AR100210A1 - Derivados de piridina con afinidad a taar - Google Patents

Derivados de piridina con afinidad a taar

Info

Publication number
AR100210A1
AR100210A1 ARP150101269A ARP150101269A AR100210A1 AR 100210 A1 AR100210 A1 AR 100210A1 AR P150101269 A ARP150101269 A AR P150101269A AR P150101269 A ARP150101269 A AR P150101269A AR 100210 A1 AR100210 A1 AR 100210A1
Authority
AR
Argentina
Prior art keywords
disorders
halogen
lower alkyl
disease
lower alkoxy
Prior art date
Application number
ARP150101269A
Other languages
English (en)
Inventor
Norcross Roger
Cecere Giuseppe
Shen Hong
Hu Yimin
Galley Guido
Pflieger Philippe
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR100210A1 publication Critical patent/AR100210A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Compuestos de fórmula (1) en el que X es CR o N; R es hidrógeno, halógeno o alquilo inferior; L es un enlace, -C(O)- o -C(O)NH-; Ar es fenilo o un grupo heteroarilo de cinco o seis miembros, que contiene uno o dos átomos de N; R¹ es halógeno, alquilo inferior, alquilo inferior sustituido con halógeno, alcoxi inferior, alcoxi inferior sustituido con halógeno o cicloalquilo; n es 0, 1, 2 ó 3; o a una sal de adición de ácido farmacéuticamente aceptable de los mismos, a todas las mezclas racémicas, a todos sus enantiómeros correspondientes y/o isómeros ópticos, que puede usarse para el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de déficit de atención e hiperactividad (TDAH), trastornos relacionados con el estrés, trastornos sicóticos, esquizofrenia, enfermedades neurológicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, migraña, hipertensión, abuso de sustancias, trastornos metabólicos, trastornos alimentarios, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo y asimilación de energía, trastornos de mal funcionamiento de la homeostasis de la temperatura corporal, trastornos del sueño y del ritmo circadiano, y trastornos cardiovasculares.
ARP150101269A 2014-04-30 2015-04-28 Derivados de piridina con afinidad a taar AR100210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/076623 WO2015165085A1 (en) 2014-04-30 2014-04-30 Morpholin-pyridine derivatives

Publications (1)

Publication Number Publication Date
AR100210A1 true AR100210A1 (es) 2016-09-21

Family

ID=53174989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101269A AR100210A1 (es) 2014-04-30 2015-04-28 Derivados de piridina con afinidad a taar

Country Status (12)

Country Link
US (1) US9840501B2 (es)
EP (1) EP3137459B1 (es)
JP (1) JP6255516B2 (es)
KR (1) KR101842382B1 (es)
CN (1) CN106255688B (es)
AR (1) AR100210A1 (es)
BR (1) BR112016022796B1 (es)
CA (1) CA2943575C (es)
MX (1) MX2016013412A (es)
RU (1) RU2690154C2 (es)
TW (1) TWI576345B (es)
WO (2) WO2015165085A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6665154B2 (ja) 2014-07-17 2020-03-13 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体及びその薬学的使用
EP3757102A1 (en) * 2016-03-17 2020-12-30 F. Hoffmann-La Roche AG 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
EP3463359A4 (en) * 2016-06-02 2020-08-26 Purdue Pharma LP SPURENAMINE-ASSOCIATED RECEPTOR-1 AGONISTS AND PARTIAL AGONISTS FOR PAIN MANAGEMENT
CN113754580B (zh) * 2020-06-05 2023-04-25 上海中泽医药科技有限公司 一种吡啶吗啉类化合物、其制备方法及其应用
TW202325305A (zh) * 2021-11-04 2023-07-01 大陸商上海翰森生物醫藥科技有限公司 ２－（芳基－２－基）嗎啉及其氘代衍生物、製備方法和應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation

Also Published As

Publication number Publication date
RU2016146560A (ru) 2018-06-01
MX2016013412A (es) 2017-01-18
WO2015165835A1 (en) 2015-11-05
CN106255688B (zh) 2019-11-08
WO2015165085A1 (en) 2015-11-05
BR112016022796B1 (pt) 2023-03-07
JP6255516B2 (ja) 2017-12-27
KR20160147033A (ko) 2016-12-21
RU2016146560A3 (es) 2018-11-26
KR101842382B1 (ko) 2018-03-26
CA2943575C (en) 2022-08-30
US9840501B2 (en) 2017-12-12
JP2017513912A (ja) 2017-06-01
BR112016022796A2 (es) 2017-08-15
CN106255688A (zh) 2016-12-21
EP3137459B1 (en) 2018-05-23
TW201546067A (zh) 2015-12-16
TWI576345B (zh) 2017-04-01
US20170044145A1 (en) 2017-02-16
CA2943575A1 (en) 2015-11-05
EP3137459A1 (en) 2017-03-08
RU2690154C2 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
AR100210A1 (es) Derivados de piridina con afinidad a taar
AR088741A1 (es) Derivados de pirazol
CO6321133A2 (es) Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns
ECSP13012896A (es) Derivados heterocíclicos de amina
ECSP12012098A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos
AR079542A1 (es) Derivados de benzamida sustituidos, proceso para su preparacion y su uso en el tratamiento de enfermedades mediadas por taars.
AR089691A1 (es) Derivados heterociclicos
MX370661B (es) Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona.
MX2017001096A (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.
AR067772A1 (es) Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos.
ECSP11010782A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
ECSP13013073A (es) Derivados de benzamida sustituida
MX2016016488A (es) Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
AR092537A1 (es) Derivados de pirazol-carboxamida
AR101339A1 (es) Derivados del 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o del 3-aminocroman-7-ilo
MX2016012624A (es) Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1).
AR093372A1 (es) Derivados de pirazina
AR059182A1 (es) Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos
EA201692404A1 (ru) Пептиды, выполняющие роль агонистов окситоцина
BR112013010558A2 (pt) derivados de di-hidro-oxazol-2-amina
CY1110087T1 (el) Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο
AR063811A1 (es) 4-imidazoles sustituidos
AR076979A1 (es) 2- aminooxazolinas como ligandos de taar1
AR067675A1 (es) 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc.
BR112016024149A2 (pt) derivados de indolin-2-ona e 1,3-di-hidro-pirrol[3,2-c]piridin-2-ona

Legal Events

Date Code Title Description
FB Suspension of granting procedure